bispecific antibodies in lung cancer - onctalk lung 2023
Published 5 months ago • 37 plays • Length 3:44Download video MP4
Download video MP3
Similar videos
-
3:21
bispecific antibodies: amivantamab - onctalk lung 2023
-
3:16
q&a: what are toxicities in bispecific antibody treatments? - onctalk lung 2023
-
3:05
antibody drug conjugate treatment in lung cancer - onctalk lung 2023
-
7:29
antibody drug conjugates: what are antibodies? - onctalk lung 2023
-
3:53
the future of bispecific antibodies - blood cancer onctalk 2023
-
1:56
types of bispecific antibodies - blood cancer onctalk 2023
-
2:30
advances in oligometastatic disease - onctalk lung 2023
-
1:49
immunotherapy and beyond for lung cancer prevention
-
3:56
bispecific antibodies in myeloma: approvals and clinical trials - blood cancer onctalk 2023
-
3:54
what are antibody drug conjugates? - onctalk lung 2023
-
2:32
toxicities in antibody drug conjugate treatment - onctalk lung 2023
-
2:06
patient role in bispecific antibody treatment - blood cancer onctalk 2023
-
6:06
bispecific antibody treatment in non-hodgkin lymphoma: epcoritamab - blood cancers onctalk 2023
-
1:37
pros and cons of bispecific antibodies - blood cancer onctalk 2023
-
4:57
q&a: is biomarker testing common in early stage nsclc? - targeted therapies in lung cancer 2023
-
2:53
management of bispecific antibodies side effects - blood cancer onctalk 2023
-
2:14
q&a: what are costs and side effects of antibody drug conjugates? - onctalk lung 2023
-
3:49
q&a: what are next steps in antibody drug conjugates? - onctalk lung 2023